Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
M Rosellini, A Marchetti, V Mollica, A Rizzo… - Nature Reviews …, 2023 - nature.com
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …
immunotherapy agents by regulatory agencies. However, objective and durable responses …
[HTML][HTML] Tumorigenesis mechanisms found in hereditary renal cell carcinoma: a review
Renal cell carcinoma is a heterogenous cancer composed of an increasing number of
unique subtypes each with their own cellular and tumor behavior. The study of hereditary …
unique subtypes each with their own cellular and tumor behavior. The study of hereditary …
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 …
TK Choueiri, DF McDermott, J Merchan… - The Lancet …, 2023 - thelancet.com
Background Few treatment options are available for patients with advanced renal cell
carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based …
carcinoma who have received previous anti-PD-1-based or anti-PD-L1-based …
[HTML][HTML] Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma
M Li, G Liu, X Jin, H Guo, S Setrerrahmane, X Xu, T Li… - Molecular cancer, 2022 - Springer
Background Although, micropeptides encoded by non-coding RNA have been shown to
have an important role in a variety of tumors processes, there have been no reports on …
have an important role in a variety of tumors processes, there have been no reports on …
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib …
Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …
pembrolizumab improved progression-free survival and overall survival compared with …
Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study
Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …
superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell …
Comparative effectiveness of front-line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma
Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with
new combination therapies demonstrating improved response rates and survival. There are …
new combination therapies demonstrating improved response rates and survival. There are …
[HTML][HTML] The emerging role of PET/CT with PSMA-targeting radiopharmaceuticals in clear cell renal cancer: an updated systematic review
A Rizzo, M Racca, S Dall'Armellina, P Rescigno… - Cancers, 2023 - mdpi.com
Simple Summary Positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals is a relatively …
prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals is a relatively …
[HTML][HTML] Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study
CP Gui, YH Chen, HW Zhao, JZ Cao, TJ Liu… - The Lancet Digital …, 2023 - thelancet.com
Background Improved markers for predicting recurrence are needed to stratify patients with
localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We …
localised (stage I–III) renal cell carcinoma after surgery for selection of adjuvant therapy. We …
A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study …
G Cazalas, C Klein, G Piana, E De Kerviler, A Gangi… - European …, 2023 - Springer
Objective Renal cell carcinomas represent the sixth-and tenth-most frequently diagnosed
cancer in men and women. Recently, percutaneous-guided thermal ablations have proved …
cancer in men and women. Recently, percutaneous-guided thermal ablations have proved …